Profund Advisors LLC Buys 42,534 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Profund Advisors LLC lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 47.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,668 shares of the biopharmaceutical company’s stock after buying an additional 42,534 shares during the quarter. Profund Advisors LLC owned about 0.12% of Catalyst Pharmaceuticals worth $1,783,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its stake in Catalyst Pharmaceuticals by 241.9% during the 2nd quarter. Barclays PLC now owns 662,685 shares of the biopharmaceutical company’s stock valued at $8,907,000 after purchasing an additional 468,846 shares during the period. Denali Advisors LLC bought a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $200,000. HRT Financial LP raised its stake in Catalyst Pharmaceuticals by 551.5% during the 1st quarter. HRT Financial LP now owns 222,178 shares of the biopharmaceutical company’s stock valued at $3,683,000 after purchasing an additional 188,073 shares during the period. LSV Asset Management grew its holdings in Catalyst Pharmaceuticals by 3.1% during the 2nd quarter. LSV Asset Management now owns 987,669 shares of the biopharmaceutical company’s stock valued at $13,274,000 after buying an additional 29,869 shares in the last quarter. Finally, Strs Ohio grew its holdings in Catalyst Pharmaceuticals by 13.2% during the 2nd quarter. Strs Ohio now owns 59,200 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 6,900 shares in the last quarter. Institutional investors own 77.27% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $13.71 on Tuesday. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of 26.37 and a beta of 1.08. The stock has a 50 day moving average price of $12.67 and a 200-day moving average price of $13.10. Catalyst Pharmaceuticals, Inc. has a one year low of $11.09 and a one year high of $22.11.

Analysts Set New Price Targets

CPRX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, August 11th. StockNews.com initiated coverage on Catalyst Pharmaceuticals in a report on Thursday, October 5th. They set a “hold” rating for the company. TheStreet cut Catalyst Pharmaceuticals from a “b” rating to a “c+” rating in a report on Thursday, November 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $27.00 target price on shares of Catalyst Pharmaceuticals in a report on Tuesday, August 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $24.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.